A discovery with major implications for cancer treatment has been made by a team of researchers from Rensselaer Polytechnic ...

Kenya is witnessing a quiet revolution in cancer care, as cutting-edge technologies anchored on AI and digital Positron Emission Tomography (PET) scans and cyclotrons are now transforming how doctors ...

GE HealthCare's Cerianna™ (fluoroestradiol F18) injection, available in the United States, is the only FDA-approved imaging agent for the detection of estrogen receptor positive (ER+) breast cancer ...

NCCN Guidelines® recommend FES PET for systemic staging in certain patients with invasive lobular cancer (ILC), which could facilitate greater diagnostic accuracy, earlier interventions, better ...

NCCN Guidelines® recommend FES PET for systemic staging in certain patients with invasive lobular cancer (ILC), which could facilitate greater diagnostic accuracy, earlier interventions, better ...

Recent articles have also demonstrated that PSMA PET may be a useful tool for risk-stratifying prostate cancer, with the SUVMax of the scan correlated with higher-grade prostate cancer.

Cancer of unknown primary site encompasses a heterogeneous group of metastatic cancers with an unidentified primary site of origin. Putative site-specific therapy and empirical chemotherapy are acc ...

Now, a new expert review by Nataniel Lester-Coll, MD and other prostate cancer specialists from the University of Vermont Cancer Center, University of Miami, Tata Memorial Hospital (India), and ...

There are limited data on performance of 18F-DCFPyL PSMA PET/CT when PSA rises to 0.2 ng/mL or less after radical prostatectomy.

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 gozetotide in PSMA-PET scans.